Skip to main content
. 2015 Aug 20;6(30):29335–29346. doi: 10.18632/oncotarget.5004

Figure 4. M2R antagonist methoctramine inhibits NF-κB p65 signaling in NSCLC cells.

Figure 4

Cells were treated with indicated concentrations of methoctramine (MT) of for 72 h. A. The expression of p-Akt, Akt, p-ERK, ERK, p-p65, p65, p-IκBα and IκBα in total cellular extracts was measured by Western blot. β-actin was used as loading control. B. The expression of p-p65, p65 in cytoplasmic extracts or nuclear extracts was measured by Western blot. β-actin or H3 histone was used as loading control for cytoplasmic extracts or nuclear extracts, respectively. The data are presented as the means ± SEM and normalized to cells treated with solvent. C. Quantification of Western blot shown in (A). The data are presented as the means ± SEM and normalized to cells treated with solvent. *P < 0.05; **P < 0.01; ***P < 0.001, compared with control.